Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
jRCTs032260681
Key facts
Open-label, single-arm trial of Lactobacillus-derived component-containing intravaginal gel in cervical intraepithelial neoplasia (CIN), sponsored by WELLBEING Yokohama. Primary endpoint: Proportion of participants showing regression of cervical intraepithelial neoplasia at 24 weeks. Started Nov 2026; status: recruiting.
Single treatment arm
Participants receive Lactobacillus-derived component-containing intravaginal gel for 24 weeks.
Premenopausal women aged 20 to 54 years with histopathologically confirmed CIN1 or CIN2 are eligible. Participants must not have used treatments that may affect the vaginal microbiota within 2 weeks before enrollment and must be able to self-administer the intravaginal gel. Pregnant or breastfeeding women, women planning pregnancy, those with immunodeficiency including HIV infection, prior cervical conization or hysterectomy, severe underlying illness, inability to self-administer the gel, or recent participation in another interventional trial are excluded.
Proportion of participants showing regression of cervical intraepithelial neoplasia at 24 weeks
Changes in vaginal microbiome composition
Changes in the relative abundance of Lactobacillus species
Changes in alpha diversity
Changes in Community State Type
Changes in vaginal pH
Changes in HPV-related parameters
Changes in cytological findings
Association between baseline vaginal microbiota and CIN regression
Beyond the preview
Full results, competitive context and analysis are in the Gosset platform.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on jRCTs032260681.